Trial Profile

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cagrilintide/semaglutide (Primary)
Indications Obesity
Focus Registrational; Therapeutic Use
Sponsors Novo Nordisk

Most Recent Events

25 Feb 2026 Planned End Date changed from 4 Jan 2028 to 17 Jan 2028.
25 Feb 2026 Planned primary completion date changed from 16 Nov 2027 to 29 Nov 2027.
25 Feb 2026 Planned initiation date changed from 9 Jun 2026 to 22 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com